அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள் Today - Breaking & Trending Today

What's the Best Aspirin Dose for Secondary Prevention of CAD?

What's the Best Aspirin Dose for Secondary Prevention of CAD?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

American College Of Cardiology Scientific Sessions , Cardiology Scientific Sessions , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள் , இருதயவியல் அறிவியல் அமர்வுகள் ,

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices
Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5 million people in the United States. Patients with this circulatory disorder may develop severe leg pain or unhealing wounds that require a minimally invasive revascularization procedure to open the blood vessels to improve blood flow.
For nearly a decade, proceduralists and surgeons have depended on devices coated with a drug called paclitaxel which reduces the need for another procedure by up to 50 percent during procedures to open the arteries of the leg. However, in the wake of a 2018 study that found a potential link between these drug-coated peripheral devices and death after two years post procedure, the FDA restricted the use of these devices for the treatment of PAD out of an abundance of caution. ....

United States , Robert Yeh , Eric Secemsky , Emily Henderson , Centers For Medicare Medicaid Services , Susanf Smith Center , American College Of Cardiology Scientific Sessions , Harvard Medical School , Outcomes Research , Beth Israel Deaconess Medical Center , Safety Assessment , Medicaid Services , American College , Scientific Sessions May , Vascular Intervention , Assistant Professor , Harvard Medical , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் ஆமாம் , எமிலி ஹென்டர்சன் , மையங்கள் க்கு மருத்துவ மருத்துவ உதவி சேவைகள் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள் , ஹார்வர்ட் மருத்துவ பள்ளி , ஔட்கம்ஸ் ஆராய்ச்சி , பெத் இஸ்ரேல் டேப்ககோணேஸ் மருத்துவ மையம் , பாதுகாப்பு மதிப்பீடு ,

Researchers: No added risk of death with drug-coated devices used for lower body procedure

Cardiologists at Beth Israel Deaconess Medical Center (BIDMC), designed the Safety Assessment of Femoropopliteal Endovascular Treatment With Paclitaxel-coated Devices (SAFE-PAD) study to provide the information necessary to make scientifically-sound regulatory decisions about the safety of these devices. ....

United States , Changyu Shen , Robert Yeh , Eric Secemsky , Marc Schermerhorn , Centers For Medicare Medicaid Services , Susanf Smith Center , Professor Of Medicine At Harvard Medical School , Boston Scientific , Harvard Medical School Shore Faculty Development Award , Outcomes Research In Cardiology , American College Of Cardiology Scientific Sessions , Blood Institute , National Heart , Outcomes Research , Beth Israel Deaconess Medical Center , Safety Assessment , Medicaid Services , American College , Scientific Sessions May , Vascular Intervention , Assistant Professor , Harvard Medical , Cook Medical , Harvard Medical School , Shore Faculty Development ,

Researchers Find No Increased Risk of Death with Drug-Coated Devices Used for Lower Extremity Revascularization

Boston - Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5. ....

United States , Changyu Shen , Robert Yeh , Eric Secemsky , Marc Schermerhorn , Centers For Medicare Medicaid Services , Susanf Smith Center , Professor Of Medicine At Harvard Medical School , Boston Scientific , Harvard Medical School Shore Faculty Development Award , Outcomes Research In Cardiology , American College Of Cardiology Scientific Sessions , Blood Institute , National Heart , Outcomes Research , Beth Israel Deaconess Medical Center , Safety Assessment , Medicaid Services , American College , Scientific Sessions May , Vascular Intervention , Assistant Professor , Harvard Medical , Cook Medical , Harvard Medical School , Shore Faculty Development ,

Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft's AI-computing Cloud

Press release content from Business Wire. The AP news staff was not involved in its creation.
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
April 21, 2021 GMT
KIRKLAND, Wash. (BUSINESS WIRE) Apr 21, 2021
Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are ....

United States , Rhonda Rhyne , Christiaan Boer , Michael Kalnoski , European Society Of Cardiology Congress , Journal Of American Heart Association , Journal Of American College Cardiology , American Heart Association Scientific Sessions , American Diabetes Association Scientific Sessions , Prevencio Inc , American College Of Cardiology Scientific Sessions , Atlas Genomics , Chief Executive , Massachusetts General Hospital , Atlas Genomic , Chief Medical Officer , European Society , Cardiology Congress , American College , Cardiology Scientific Sessions , American Journal , Open Heart , Clinical Cardiology , American Heart Association , Cardiovascular Disease , Machine Learning ,